Summit: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data (SMMT)
· seekingalpha.com
Summit Therapeutics is upgraded to a 'Buy' following FDA acceptance of its BLA for ivonescimab + chemotherapy in EGFR-mutant NSCLC. Click for more on SMMT stock.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...